Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GlucoTrack, Inc. (NASDAQ: GCTK) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a smaller reporting company and Nasdaq-listed medical device issuer, GlucoTrack uses these filings to disclose information about its implantable Continuous Blood Glucose Monitor (CBGM) program, financial condition, capital structure, and corporate governance.
Through this page, readers can review current reports on Form 8‑K, where GlucoTrack reports material events such as clinical and financial press releases, special stockholder meetings, financing agreements, and warrant repurchases. Registration statements like Form S‑1 detail equity purchase arrangements and potential resales of common stock tied to committed equity facilities, while proxy materials such as DEF 14A describe stockholder proposals related to share issuances and special meetings.
Annual and quarterly reports (Forms 10‑K and 10‑Q, referenced in company communications) contain management’s discussion and analysis of operating results, descriptions of the CBGM development program, and risk factors that include the need for additional capital, clinical and regulatory uncertainties, and other considerations typical for an investigational medical device company. These filings also outline GlucoTrack’s status as a smaller reporting company and its listing on the Nasdaq Capital Market under the symbol GCTK.
On Stock Titan, GlucoTrack filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as equity line terms, private placements, warrant transactions, and clinical disclosure language. Real-time updates from EDGAR, along with structured access to current reports, registration statements, and proxy materials, allow investors and researchers to follow how GlucoTrack describes the evolution of its implantable CBGM platform, financing strategy, and corporate actions in its official SEC record.
Glucotrack, Inc. has called a special virtual stockholder meeting on October 31, 2025 to seek approval for a major stock issuance tied to a financing deal with Sixth Borough Capital Fund, LP. The company entered into a purchase agreement on September 11, 2025 that allows Sixth Borough to buy up to $20.0 million of Glucotrack common stock over 24 months through various purchase types at discounts to market prices. Because the potential share issuances under this agreement, including 60,000 commitment shares, may exceed 20% of the 899,410 shares outstanding as of the agreement date, Nasdaq Listing Rule 5635(d) requires stockholder approval. The board unanimously recommends voting “FOR” approval of this Issuance Proposal and a related proposal that would let the board adjourn the meeting, if needed, to gather more votes.
Glucotrack, Inc. filed a preliminary proxy statement for a special stockholder meeting to be held on
The document includes a security ownership table showing named individuals and trusts, with John A. Ballantyne (and an associated revocable trust) holding
GlucoTrack, Inc. entered into a Purchase Agreement and Registration Rights Agreement with Sixth Borough Capital Fund, LP under which the investor committed to purchase up to $20.0 million of the company's common stock, subject to conditions. The facility permits intraday purchases subject to a daily dollar cap of $1,000,000 and a volume limit tied to 100% of five-day average trading volume. Intraday purchases price at the greater of 95% of the lowest intraday trading price or the prior business day closing sale price. The company may pay a Commitment Fee in cash, shares, or pre-funded warrants; if paid in securities those shares will be priced based on a one-day or five-day closing price metric. GlucoTrack must file a registration statement within 15 days covering the commitment fee shares and the maximum purchase shares and use best efforts to have it declared effective within 45 days and to keep it continuously effective for resale until obligations are satisfied.
Glucotrack, Inc. filed a Form S-8 to register 124,555 additional shares of its common stock for issuance under the Glucotrack, Inc. 2024 Equity Incentive Plan. These additional shares reflect an amendment increasing the plan’s maximum aggregate share limit to 125,000, effective May 22, 2025, as adjusted for the company’s one-for-sixty reverse stock split effective June 13, 2025.
The filing uses General Instruction E of Form S-8 to add to a prior S-8 that originally covered 535,127 shares, which were subsequently adjusted to 26,757 and then 445 shares through earlier reverse stock splits. The company also incorporates by reference its recent annual, quarterly, and current reports and related charter and plan documents.
GlucoTrack, Inc. (GCTK) 10-Q highlights key liquidity, capital-raising and equity-structure actions through June 30, 2025. The company reported cash and cash equivalents of $9,555 and continued operating losses, with multiple periods showing losses (examples include $11,589, $7,416, $4,756, $4,489 reflected across periods). Share count rose materially to 899,410 shares outstanding as of June 30, 2025 from 13,409 at 12/31/2024 following public offerings, private placements and warrant exchanges.
The company completed a February 2025 1-for-20 reverse split and a June 2025 1-for-60 reverse split, and stockholders approved increasing authorized common shares from 100,000,000 to 250,000,000. Financing activity included at-the-market sales and registered offerings generating net proceeds such as $4,320, $3,643, and a private placement raising approximately $500. Derivative warrant liabilities changed, with a June 30, 2025 reported balance movement (fair value adjustments noted). Management states it plans to finance operations via equity or debt and notes there is no assurance of obtaining sufficient financing to continue as a going concern.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
